AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 21 min read$CODX

Co-Diagnostics, Inc. (CODX): Submission of Matters to a Vote of Security Holders

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. As previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). However, the Company did not achieve a quorum a

Original reporting
SEC EDGAR 8-K
Published Oct 2, 2026, 11:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 10:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$CODX
Bearish
medium confidence
Mentioned
$CODX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CODXBearishLow
01

Why it matters

The repeated failure to convene a quorum raises questions about shareholder engagement and may affect confidence in the company's governance.

02

Market read

A governance filing with minimal immediate market impact; likely neutral to slightly negative sentiment.

03

What to watch

Potential upcoming proxy proposals or board changes that could affect future governance.

Relevance 6/10Novelty 4/10Timing: meeting adjourned to Oct 14 2026

Background

Co‑Diagnostics filed an 8‑K announcing that its annual shareholder meeting could not achieve a quorum and was rescheduled multiple times.

Company-level read

Ticker impact

$CODXBearishMedium confidence
Context

SEC 8‑K reports the annual shareholder meeting failed to achieve a quorum and has been adjourned to Oct 14, 2026.

Expected impact

likely downside pressure as investors assess governance risk

Evidence & confidence

No business‑operating impact, but repeated meeting failures can erode investor confidence.

Market effects

Sector

Limited; primarily a corporate‑governance issue for a small biotech.

Regional

None

Global

None

Counterpoint

What could challenge this read

Investors may view the delay as a short‑term technical issue without long‑term impact.

Key entities

  • company
    Co‑Diagnostics, Inc.

    US‑listed biotech (ticker CODX) reporting the missed quorum.

  • person
    Dwight Egan

    CEO who signed the filing.

Read at source← All news

Related articles

AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min
AUG 6
$CODXMed

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Co-Diagnostics (Nasdaq: CODX) said it submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The filing follows clinical studies of 1,400 symptomatic patients and analytical work across 27 studies and 10,000+ PCR runs. If granted, the CLIA waiver would enable decentralized point-of-care use; the platform is not yet for sale.

prnewswire.com2 min
JUL 1
$CODXMed

EXCLUSIVE: Co-Diagnostics Reaches Regulatory Milestone for PCR Respiratory Test Platform - Co-Diagnostics

Co-Diagnostics (NASDAQ:CODX) said it completed clinical and analytical performance studies for its Co-Dx PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro instrument. The company plans to include the results in its FDA submission package for a Dual 510(k) and CLIA Waiver by Application targeted for Q3 2026. Shares were down 0.65% premarket to $3.08.

benzinga.com4 min
MAY 29
$SPRCMedAI 8/10

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

rttnews.com6 min